Author:
Fernandez Mercedes,Mejias Marc,Angermayr Bernhard,Garcia-Pagan Juan Carlos,Rodés Juan,Bosch Jaime
Reference22 articles.
1. Pathophysiology of portal hypertension;Bosch;Gastroenterol Clin North Am,1992
2. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice;Fernandez;Gastroenterology,2004
3. Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal hypertensive rats;Fernandez;Gastroenterology,1995
4. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types;Fong;Cancer Res,1999
5. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent;Mendel;Anticancer Drug Des,2000
Cited by
184 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献